Nonalcoholic fatty liver disease (NAFLD), defined by fatty infiltration of the liver in the absence of excess alcohol consumption, affects an estimated 30% of adults in the United States. A proportion of people with NAFLD will develop progressive, inflammatory nonalcoholic steatohepatitis (NASH), which can progress to liver cirrhosis and liver failure. NAFLD is expected to be the most common indication for liver transplantation by the year 2020. We hypothesize that among adults with NAFLD, aspirin will reduce intrahepatic lipid content, as quantified by 1H magnetic resonance spectroscopy (1H-MRS).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
80
Aspirin 81mg tablets will be given once daily, for the duration of the clinical trial.
Identical, blinded placebo tablets will be given once daily, for the duration of the clinical trial.
Massachusetts General Hospital
Boston, Massachusetts, United States
Absolute Change in Intrahepatic Lipid Content, by 1H-MRS
Absolute percentage change in intrahepatic lipid content, quantified by 1H-MRS
Time frame: 6 months
Relative Change in Intrahepatic Lipid Content
Relative percentage point change in intrahepatic lipid content
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.